Immunovant (IMVT) Equity Ratio (2018 - 2026)
Immunovant filings provide 8 years of Equity Ratio readings, the most recent being 0.94 for Q4 2025.
- Quarterly Equity Ratio rose 11.86% to 0.94 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.94 through Dec 2025, up 11.86% year-over-year, with the annual reading at 0.91 for FY2025, 1.69% down from the prior year.
- Equity Ratio hit 0.94 in Q4 2025 for Immunovant, up from 0.89 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.95 in Q4 2023 and bottomed at 0.84 in Q4 2024.
- Average Equity Ratio over 5 years is 0.91, with a median of 0.92 recorded in 2024.
- The largest annual shift saw Equity Ratio decreased 12.27% in 2024 before it rose 11.86% in 2025.
- Immunovant's Equity Ratio stood at 0.93 in 2021, then dropped by 2.27% to 0.91 in 2022, then rose by 5.06% to 0.95 in 2023, then decreased by 12.27% to 0.84 in 2024, then increased by 11.86% to 0.94 in 2025.
- Per Business Quant, the three most recent readings for IMVT's Equity Ratio are 0.94 (Q4 2025), 0.89 (Q3 2025), and 0.92 (Q2 2025).